Milestone Pharmaceuticals Inc. (MIST)
| Market Cap | 147.79M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -51.93M |
| Shares Out | 97.87M |
| EPS (ttm) | -0.78 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 578,163 |
| Open | 1.530 |
| Previous Close | 1.530 |
| Day's Range | 1.490 - 1.547 |
| 52-Week Range | 0.625 - 2.750 |
| Beta | 0.52 |
| Analysts | Strong Buy |
| Price Target | 7.50 (+396.69%) |
| Earnings Date | Aug 15, 2025 |
About NVRO
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company’s lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to deve... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for MIST stock is "Strong Buy." The 12-month stock price target is $7.5, which is an increase of 396.69% from the latest price.
News
Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution
Despite the CRL setback and heavy dilution, we remain optimistic on etripamil's long-term market potential and Milestone's investment thesis. The recent $52.5 million equity raise was poorly timed and...
Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge
U.S. stocks traded mostly lower toward the end of trading, with the Dow Jones index dipping more than 250 points on Friday.
Milestone Pharmaceuticals Announces Pricing of $52.5 Million Public Offering of Common Shares, Pre-Funded Warrants, Series A Common Warrants and Series B Common Warrants
MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercializati...
Milestone Pharmaceuticals Announces Proposed Public Offering
MONTREAL, Quebec and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST) today announced that it has commenced an underwritten public offeri...
Milestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray
New PDUFA Action Date of December 13, 2025 $75 Million Royalty Purchase Agreement Payment from RTW Extended Through 2025 MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Phar...
Watch Milestone Pharmaceuticals For (Likely) Upcoming FDA Approval For Cardamyst
I rate Milestone Pharmaceuticals Inc. a Strong Buy under $2, expecting FDA approval for Cardamyst in early 2026 after addressing recent regulatory setbacks. Cardamyst offers a unique, self-administere...
Milestone Pharmaceuticals Submits Response to the FDA's CRL for CARDAMYST (etripamil) Nasal Spray for PSVT Following Type A Meeting
MONTREAL and CHARLOTTE, N.C., June 16, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced submission of its response to the U.S. Food and Drug Administration (FDA)...
Milestone Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
MONTREAL AND CHARLOTTE, N.C., May 28, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that Amit Hasija, Chief Financial Officer, and Lorenz Muller, Chief Commer...
Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Resolution of CRL Manufacturing issues in progress - Type A meeting requested N o clinical safety or efficacy concerns raised by FDA MONTREAL and CHARLOTTE, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- Mile...
Stock Picks From Seeking Alpha's March 2025 New Analysts
In March, we welcomed 30 new analysts to Seeking Alpha, and in this article we are showcasing their stock picks and investment strategies. Our analysts covered a diverse set of industries—including IT...
Milestone Pharmaceuticals Shares Hit New Low After FDA Rejects Etripamil
Milestone Pharmaceuticals shares collapsed on Friday after the U.S. Food and Drug Administration once again turned away the biopharmaceutical company's proposed etripamil nasal spray to treat a type o...
US FDA declines to approve Milestone Pharma's heart rhythm nasal spray
The U.S. Food and Drug Administration has declined to approve Milestone Pharmaceuticals' nasal spray to treat a type of heart condition, the company said on Friday.
FDA Issues Complete Response Letter for Etripamil for PSVT
CRL focused on CMC; no clinical issues relating to etripamil raised $69.7M in cash, cash equivalents and short-term investments as of December 31, 2024 MONTREAL and CHARLOTTE, N.C., March 28, 2025 (G...
Milestone Pharmaceuticals: A Compelling Value Proposition For Patients And Payers
In December 2023, Milestone Pharmaceuticals received an RTF letter from the FDA for insufficient TEAE data in their NDA filing, which precipitated a rapid decline in its share price. With an upcoming ...
Milestone Pharmaceuticals to Present Clinical Data on Etripamil at the American College of Cardiology
MONTREAL and CHARLOTTE, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovati...
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Regulatory and Corporate Update
FDA PDUFA review goal date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MONTREAL and CHARLOTTE, N.C., March 04, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, i...
Milestone® Pharmaceuticals to Present at the TD Cowen 45th Annual Health Care Conference
MONTREAL and CHARLOTTE, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that President and CEO, Joe Oliveto, will present at the TD Cowen 45th An...
Milestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for Etripamil
MONTREAL and CHARLOTTE, N.C., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovativ...
Milestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025
MONTREAL and CHARLOTTE, N.C., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovati...
Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC
- PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)
Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025 NDA for CARDAMYST™ in PSVT under review by FDA; PDUFA March 27, 2025
Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China
MONTREAL and CHARLOTTE, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovat...
Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors
MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovat...
Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update
– NDA for CARDAMYST™ in PSVT accepted by FDA in 2Q 2024; PDUFA in March 2025 – Cash of $83.3 million as of June 30, 2024 expected to fund operations into 2026 – Stuart Duty and Andrew Saik Appointed a...